Generated by AI
BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurodegenerative disorders and advanced liver disease. Its current pipeline centers on investigational drug candidates such as bezisterim, being studied for conditions including Alzheimer’s disease, Parkinson’s disease, and long COVID, and BIV201, which is being developed for complications related to liver cirrhosis and ascites. The company’s work is aimed at addressing chronic, debilitating illnesses through targeted pharmaceutical approaches that seek to reduce inflammation, support neurological function, and manage liver-related fluid retention. BioVie Inc. operates within the biotechnology sector and concentrates on diseases with significant unmet medical needs, making its programs relevant to both neuroscience and hepatology-focused drug development.
Website680 W. Nye Lane
Carson City, NV, 89703
United States
The latest articles about BIVI.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said new biomarker analyses from its Long COVID trial identified two patient groups that responded differently to its drug bezisterim. The company said the findings could inform the design of future Long COVID studies. Results from the ADDRESS-LC...
Summary of Nov 3's posts. Generated by AI.
Summary of Aug 21's posts. Generated by AI.
Summary of Nov 3's posts. Generated by AI.
Investors talking about BIVI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.